Human tumours typically harbour a remarkable number of somatic mutations. If presented
on major histocompatibility complex class I molecules (MHCI), peptides containing these …

Analogue peptides with enhanced binding affinity to major histocompatibility class (MHC) I
molecules are currently being used in cancer patients to elicit stronger T cell responses …

Binding of peptide/MHC (pMHC) complexes by TCR initiates T cell activation. Despite long
interest, the exact relationship between the biochemistry of TCR/pMHC interaction …

Immunogenicity of tumor-associated antigens (TAA) is often weak because many TAA are
autoantigens for which the T-cell repertoire is sculpted by tolerance mechanisms …

CD8 engagement is believed to be a critical event in the activation of naive T cells. In this
communication, we address the effects of peptide-MHC (pMHC)/TCR affinity on the …

In this study, we suggest that CD8 levels on T cells are not static, but can change and, as a
result, modulate CD8+ T cell responses. We describe three models of CD8 modulation using …

Lymphocytic choriomeningitis virus infection of H-2 b mice generates a strong CD8+ CTL
response mainly directed toward three immunodominant epitopes, one of which, gp33, is …

Here we describe a multiplex, fluorescence‐based, in vivo cytotoxic T‐cell assay using the
three vital dyes carboxyfluorescein diacetate succinimidyl ester, cell trace violet, and cell …

T-cell activation is a crucial step in mounting of the immune response. The dynamics of T-
cell receptor (TCR) specific recognition of peptide presented by major histocompatibility …

The major histocompatibility complex class I (MHCI) is a large gene family, with over 20
members in mouse. Some MHCIs are well-known for their critical roles in the immune …